Current management of diabetes mellitus and future directions in care
- PMID: 26453594
- DOI: 10.1136/postgradmedj-2014-133200
Current management of diabetes mellitus and future directions in care
Abstract
The last 90 years have seen considerable advances in the management of type 1 and type 2 diabetes. Prof MacLean of Guy's Hospital wrote in the Postgraduate Medical Journal in 1926 about the numerous challenges that faced patients and their healthcare professionals in delivering safe and effective diabetes care at that time. The discovery of insulin in 1922 heralded a new age in enabling long-term glycaemic control, which reduced morbidity and mortality. Thirty years later, the first oral agents for diabetes, the biguanides and sulfonylureas, appeared and freed type 2 patients from having to inject insulin following diagnosis. Improvements in insulin formulations over the decades, including rapid-acting and long-acting insulin analogues that more closely mimic physiological insulin secretion, have increased the flexibility and efficacy of type 1 diabetes management. The last two decades have seen major advances in technology, which has manifested in more accurate glucose monitoring systems and insulin delivery devices ('insulin pump'). Increased understanding of the pathophysiological deficits underlying type 2 diabetes has led to the development of targeted therapeutic approaches such as on the small intestine (glucagon-like peptide-1 receptor analogues and dipeptidyl-peptidase IV inhibitors) and kidneys (sodium-glucose cotransporter-2 inhibitors). A patient-centred approach delivered by a multidisciplinary team is now advocated. Glycaemic targets are set according to individual circumstances, taking into account factors such as weight, hypoglycaemia risk and patient preference. Stepwise treatment guidelines devised by international diabetes organisations standardise and rationalise management. Structured education programmes and psychological support are now well-established as essential for improving patient motivation and self-empowerment. Large multicentre randomised trials have confirmed the effectiveness of intensive glycaemic control on microvascular outcomes, but macrovascular outcomes and cardiovascular safety remain controversial with several glucose-lowering agents. Future directions in diabetes care include strategies such as the 'bionic pancreas', stem cell therapy and targeting the intestinal microbiome. All of these treatments are still being refined, and it may be several decades before they are clinically useful. Prevention and cure of diabetes is the Holy Grail but remain elusive due to lack of detailed understanding of the metabolic, genetic and immunological causes that underpin diabetes. Much progress has been made since the time of Prof MacLean 90 years ago, but there are still great strides to be taken before the life of the patient with diabetes improves even more significantly.
Keywords: DIABETES & ENDOCRINOLOGY.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Similar articles
-
Diabetes technology and treatments in the paediatric age group.Int J Clin Pract Suppl. 2011 Feb;(170):76-82. doi: 10.1111/j.1742-1241.2010.02582.x. Int J Clin Pract Suppl. 2011. PMID: 21323816 Review.
-
Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial.Lancet Diabetes Endocrinol. 2016 Mar;4(3):233-243. doi: 10.1016/S2213-8587(15)00489-1. Epub 2016 Feb 3. Lancet Diabetes Endocrinol. 2016. PMID: 26850709 Free PMC article. Clinical Trial.
-
How technology has changed diabetes management and what it has failed to achieve.Diabetes Metab. 2011 Dec;37 Suppl 4:S57-64. doi: 10.1016/S1262-3636(11)70967-3. Diabetes Metab. 2011. PMID: 22208712 Review.
-
The Impact of Technology on Current Diabetes Management.Pediatr Clin North Am. 2015 Aug;62(4):873-88. doi: 10.1016/j.pcl.2015.04.005. Epub 2015 May 16. Pediatr Clin North Am. 2015. PMID: 26210622 Review.
-
Closing the Loop.Diabetes Technol Ther. 2016 Feb;18 Suppl 1:S29-42. doi: 10.1089/dia.2016.2504. Diabetes Technol Ther. 2016. PMID: 26836427 Review. No abstract available.
Cited by
-
Exploring patient's perspective of barriers to diabetic medication adherence in Jazan, Saudi Arabia, using the social determinants of health model.SAGE Open Med. 2024 Aug 18;12:20503121241271820. doi: 10.1177/20503121241271820. eCollection 2024. SAGE Open Med. 2024. PMID: 39161401 Free PMC article.
-
Perspectives of older people with uncontrolled type 2 diabetes mellitus towards medication adherence: A qualitative study.PLoS One. 2023 Aug 10;18(8):e0289834. doi: 10.1371/journal.pone.0289834. eCollection 2023. PLoS One. 2023. PMID: 37561681 Free PMC article.
-
An Update on the Molecular and Cellular Basis of Pharmacotherapy in Type 2 Diabetes Mellitus.Int J Mol Sci. 2023 May 26;24(11):9328. doi: 10.3390/ijms24119328. Int J Mol Sci. 2023. PMID: 37298274 Free PMC article. Review.
-
Editorial: Psychological Interventions to Improve Diabetes Self-Management.Front Clin Diabetes Healthc. 2022 Jul 18;3:931125. doi: 10.3389/fcdhc.2022.931125. eCollection 2022. Front Clin Diabetes Healthc. 2022. PMID: 36992746 Free PMC article. No abstract available.
-
Telehealth System Based on the Ontology Design of a Diabetes Management Pathway Model in China: Development and Usability Study.JMIR Med Inform. 2022 Dec 19;10(12):e42664. doi: 10.2196/42664. JMIR Med Inform. 2022. PMID: 36534448 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical